Deals Of The Week: Sanofi/Genfar, Janssen/Astellas, Evotec/Bayer
It was an important week for Celgene, which made two cancer deals while producing data that help validate its $2.9 billion buyout of Abraxane.
You may also be interested in...
Sanofi sees China sales dip slightly in Q3, but expects sales to rebound in the next few quarters as it sets its sights on other emerging markets such as Vietnam and Africa. Bristol Myers Squibb piggybacks on brands like Baraclude and Orencia to grow deeper in China and greater Asia.
VentiRx’s immunotherapy approach has created a compound, VTX-2337, offering potential in a variety of cancers and complementary to numerous standard-of-care backbones.
Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe
Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.